Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD
https://doi.org/10.18093/0869-0189-2018-28-1-61-68
Abstract
About the Authors
S. K. ZyryanovRussian Federation
Sergey K. Zyryanov, Doctor of Medicine, Professor, Head of Department of General and Clinical Pharmacology.
ul. Miklukho-Maklaya 6, Moscow, 117198.
I. N. D'yakov
Russian Federation
Il'ya N. D'yakov, Candidate of Medicine, Head of Laboratory of Biosynthesis of Immunoglobulines.
: Malyy Kazennyy per. 5A, Moscow, 105064; ul. Aviamotornaya 50, build. 2, Moscow, 111024.
References
1. Sinopal'nikov A.I., Zaytsev A.A. Antibacterial therapy of acute exacerbation of chronic bronchitis/chronic obstructive pulmonary disease: key points. Meditsinskiy sovet. 2017; 18: 14–20 (in Russian). DOI: 10.21518/2079-701X-2017-18-14-20.
2. Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65 (6): 473–479. DOI: 10.1136/thx.2009.125435.
3. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.
4. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.
5. Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488. DOI: 10.1007/s40265-014-0194-8.
6. Banerji D., Fogel R., Patalano F. Indacaterol/glycopyrronium: a dual bronchodilator for COPD. Drug Discov. Today. 2018; 23 (1): 196–203. DOI: 10.1016/j.drudis.2017.10.015.
7. Zyryanov S.K., Frolov M.Yu., Belevskiy A.S. Clinical efficacy and cost-effectiveness of indacaterol / glycopyrronium bromide fixed combination in chronic obstructive pulmonary disease. Prakticheskaya pul'monologiya. 2016; (4): 76–84 (in Russian).
8. Donohue J. F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Intern. J. COPD. 2017: 12: 367–381. DOI: 10.2147/COPD.S119908.
9. Keininger D.L., Price D., Viswanad B. et al. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey. J. Thorac. Dis. 2016; 8 (Suppl. 5): AB036. DOI: 10.21037/jtd.2016.s036.
10. Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J. 2017; 49 (2): 1601794. DOI: 10.1183/13993003.01794-2016
Review
For citations:
Zyryanov S.K., D'yakov I.N. Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD. PULMONOLOGIYA. 2018;28(1):61-68. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-1-61-68